Quercerin |
80 mg/kg twice a week |
– |
In vivo |
Induced apoptosis, induced ER stress, activated p-STAT3/ Bcl2 axis, induced protective authophagy, |
[78] |
34′7TMQ |
– |
Epithelial and fibroblast ovarian cancer cell lines |
In vitro |
Inhibited cell migration and invasion, inhibited expression of uPA and MMP-2 |
[90] |
Quercetin |
A dose range |
Metastatic ovarian cancer cell line |
In vitro |
Decreased viability, induced apoptosis, decreased Bcl-2 and Bcl-xL, increased caspase-3, caspase-p, Bid, Bad, Bax, cytochrome c |
[79] |
Quercetin |
100 μM |
Multi-drug resistant ovarian cancer cell line |
In vitro |
Increased ER stress, prolonged DNA repair, increased expression of p53, p21 and Bax, decreased expression of Bcl-2, induced radio-sensitization, |
[81] |
Quercetin |
– |
Human ovarian cancer xenograft model |
In vivo |
increased radiation-induced cell death, increased p53, increased ER stress |
|
Quercetin |
A dose range |
Cisplatin sensitive and resistant cell lines |
In vitro |
Enhanced cisplatin cytotoxicity, increased ER stress, suppressed STAT-3 phosphorylation, decreased expression of Bcl-2, |
[82] |
|
40 mg/kg once a week |
Human ovarian cancer xenograft model |
In vivo |
Suppressed STAY-3 phosphorylation, decreased Bcl-2 expression, induced apoptosis |
|
Quercetin |
A dose range |
Epithelial ovarian cancer cell line and its CIS-resistant cell line |
In vitro |
Decreased expression of cyclin D1 |
[85] |
Quercetin |
A dose range |
Epithelial ovarian cancer cell line |
In vitro |
Inhibited proliferation, induced apoptosis, decreased survivin, induced cell cycle arrest |
[86] |
Nano-formulation of quercetin |
A dose range |
Ovarian endometrioid adenocarcinoma |
In vitro |
Inhibited growth, induced apoptosis, activated caspase-3 and caspase-9, decreased expression of MCL-1 and Bcl-2, increased expression of Bax |
[80] |
|
A dose range |
Human ovarian cancer xenograft model |
In vivo |
Inhibited growth, induced apoptosis, inhibited angiogenesis |
|
Quercetin |
A dose range |
Epithelial and drug resistant ovarian cancer cell lines |
In vitro |
Decreased ROS, increased anti-oxidant enzymes, inhibited apoptosis |
[91] |
|
|
Human ovarian cancer xenograft model |
In vivo |
Increased anti-oxidant enzymes expression, reduced ROS, decreased anti-neoplastic drug’s efficacy |
|
Lipo-Que |
– |
CIS-resistant and CIS-sensitive ovarian cancer cell lines |
In vitro |
Inhibited proliferation, induced apoptosis, induced cell cycle arrest |
[83] |
|
|
Human ovarian cancer xenograft model |
In vivo |
Inhibited tumor growth, inhibited proliferation, induced apoptosis |
|
Quercetin |
2 mg / kg |
Human ovarian cancer xenograft model |
In vivo |
Increased TRAIL sensitization, inhibited tumor growth, increased caspase-3, induced apoptosis |
[88] |
Quercetin |
10 microM |
Ovarian serous adenocarcinoma |
In vitro |
Increased TGF beta 1 activity |
[89] |
Quercetin |
A dose range |
Metastatic ovarian serous adenocarcinoma |
In vitro |
Inhibited PI kinase, decreased IP3 levels |
[87] |